Table:

Model parameters and calibration data

	Sampling Distribution	Reference
HIV prevalence among people who inject drugs	Triangular distributions that differ by country or territory	1,16
HCV antibody prevalence among people who inject drugs	Triangular distributions that differ by country or territory	1
Population size of people who inject drugs	Triangular distributions that differ by country or territory	1,16
Proportion of people who inject drugs that are unstably housed	Triangular distributions that differ by country or territory	1
Average duration of injecting	Triangular distributions that differ by country or territory	17
Proportion of HCV infections that spontaneously clear	Uniform (0·22–0·29%)	18
Relative increase in HIV transmission risk if unstably housed	Lognormal distribution with mean 1·39 (95% CI 1·06–1·84)	5
Relative increase in HCV transmission risk if unstably housed	Lognormal distribution with mean 1·64 (95% CI 1·43–1·89)	5
Average duration of unstable housing (years)	Uniform (0·25–2)	19-22
Annual rate of non-HIV mortality*	Triangular distributions that differ by country, region, or territory	23
Average number of years before HIV mortality	Differs by country depending on country-level ART coverage	25-27

ART=antiretroviral therapy. HCV=hepatitis C virus.

^*Regional estimates used as available; otherwise estimates for high-income and low-income and middle-income countries were used as appropriate.